The Best FDA Decision On Peptide Authorization Isn’t Yes Or No
The Best FDA Decision On Peptide Authorization Isn't Yes Or No The Food and Drug Administration's approach to regulating therapeutic peptides has reached an inflection point, and according to a recent analysis published by Forbes, the most consequential path forward for the agency may not be a simp...
Phoenix doctor urges caution as FDA moves to regulate popular peptides
Phoenix Doctor Urges Caution as FDA Moves to Regulate Popular Peptides A Phoenix-based physician is warning consumers to exercise caution amid growing regulatory scrutiny of peptide therapies, as the U.S.
FDA issues warning letters to five unapproved GLP-1 websites
FDA Issues Warning Letters to Five Unapproved GLP-1 Websites The U.S. Food and Drug Administration has issued warning letters to five websites for allegedly marketing unapproved versions of GLP-1 receptor agonist products, according to a report from pharmaphorum.com.
FDA cracks down on online black market for weight loss peptides
FDA Targets Illicit Online Sales of Weight Loss Peptides Amid Surging Demand The U.S. Food and Drug Administration is intensifying scrutiny of an expanding online black market for weight loss peptides, according to a report from Pharmaceutical Technology.
Aurobindo Pharma’s Auropeptides US FDA Inspection Ends With One Finding
Aurobindo Pharma's Peptide Manufacturing Unit Clears FDA Inspection With Single Observation Aurobindo Pharma's specialized peptide manufacturing subsidiary, Auropeptides, has concluded a US Food and Drug Administration inspection with only one observation noted, according to a report by Sahi.
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last
Hims & Hers Shares Dip as FDA Signals Scrutiny of GLP-1 Marketing by Telehealth Providers Shares of Hims & Hers Health slipped in overnight trading after reports emerged that the U.S.
The FDA Is Right to Prohibit Mass Production of Unapproved GLP-1 Drugs
FDA Is Right to Prohibit Mass Production of Unapproved GLP-1 Drugs, Legal Experts Say The Food and Drug Law Institute (FDLI) has weighed in on one of the most contentious regulatory disputes in pharmaceutical law today, arguing that the Food and Drug Administration's efforts to curb mass production...
5 Things to Know About the FDA's Peptide Reversal
FDA's Shifting Stance on Peptides Sends Ripples Through Compounding Industry The U.S.
FDA Advisory Committee Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead
FDA Advisory Committee Voted Yes on Six Peptides.
July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list
FDA Advisory Panel Narrowly Approves Adding Unapproved Peptides to Compounding List A Food and Drug Administration advisory panel voted narrowly on July 27, 2026, to recommend adding certain unapproved peptide drugs to the agency's compounding lists, according to reporting from the Partnership for ...
FDA on Peptides: A New Landscape for Compounders
FDA on Peptides: A New Landscape for Compounders Washington, D.C.
An FDA Advisory Panel Voted to Ease Restrictions on 6 Controversial Peptides—Here’s What That Means
FDA Advisory Panel Reportedly Backs Loosening Restrictions on Six Contested Peptides A Food and Drug Administration advisory panel has reportedly voted in favor of easing restrictions on six peptides that have been at the center of an ongoing regulatory dispute, according to a report from Allure.
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides State legislatures and pharmacy boards across the country are moving to impose their own restrictions on compounded GLP-1 medications and peptide products, adding a new layer of regulatory complexity for an industry t...
Are Peptides Illegal in California? State Laws Explained
Are Peptides Illegal in California? What the Current Rules Actually Say Confusion over the legal status of therapeutic peptides — from BPC-157 to CJC-1295 and semaglutide-adjacent compounds — has intensified as more Californians turn to wellness clinics, telehealth providers, and compounding ph...
Texas Peptide Laws 2024: Regulations for BPC-157, TB-500, and More
Texas Peptide Laws 2024: What Residents and Businesses Need to Know About BPC-157, TB-500, and Compounded Peptide Therapies As interest in peptide therapies such as BPC-157 and TB-500 continues to grow among Texas consumers, wellness clinics, and compounding pharmacies, questions about the state's ...
FDA panel supports broadening access to peptides popular on the gray market
FDA Advisory Panel Signals Openness to Expanding Legal Access to Popular Peptide Compounds A Food and Drug Administration advisory panel has expressed support for broadening legitimate access to certain peptide compounds that have gained significant popularity through gray-market channels, accordin...
How the FDA Regulates Peptides
How the FDA Regulates Peptides: A Growing Regulatory Gray Zone Under Scrutiny The Food and Drug Administration's oversight of peptide-based products has come under renewed examination, as a new analysis from the Johns Hopkins Bloomberg School of Public Health lays out the complex and often confusin...
FDA staff and peptide enthusiasts set to clash at advisory panel
FDA Advisory Panel Set to Weigh In on Contested Peptide Compounds Amid Growing Industry Tension A forthcoming Food and Drug Administration advisory committee meeting is expected to become a flashpoint in the ongoing debate over the regulatory status of popular research and wellness peptides, accord...
FDA’s Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype
FDA's Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype A recent Forbes report has drawn renewed attention to the Food and Drug Administration's ongoing scrutiny of the peptide industry, highlighting what the publication frames as a growing public health ch...
FDA panel backs 6 peptides despite its own scientists’ objections
FDA Panel Backs Six Peptides Despite Internal Scientific Objections A Food and Drug Administration advisory panel has voted to support the use of six peptide compounds for compounding, moving forward despite documented objections from the agency's own scientific staff, according to a report from Ma...
FDA puts former Rancho Santa Fe pharmacist on notice for selling unapproved weight-loss injections online
FDA Targets Former Rancho Santa Fe Pharmacist Over Online Weight-Loss Injection Sales The U.S.
July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list
FDA Advisory Panel Narrowly Approves Adding Unapproved Peptides to Compounding List A Food and Drug Administration advisory panel voted narrowly on July 27, 2026, to recommend adding a group of unapproved peptide drugs to the agency's compounding list, according to reporting from the Partnership fo...
FDA advisers back first four of seven unapproved peptides under review for looser rules
FDA Advisory Panel Recommends Looser Rules for Four Unapproved Peptides, With Three More Under Review A Food and Drug Administration advisory committee has voted to support looser regulatory treatment for four of seven unapproved peptide compounds currently under agency review, according to a repor...
FDA panel to review popular peptides amid persistent consumer appetite
FDA Panel to Review Popular Peptides Amid Persistent Consumer Appetite The U.S.
FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists
FDA Advisory Panel Backs Expanded Peptide Compounding Over Objections From Agency's Own Scientists A Food and Drug Administration advisory panel has voted to recommend adding certain peptides to the list of substances that compounding pharmacies are permitted to use, a decision reached despite push...
FDA panel votes to loosen restrictions for controversial peptides
FDA Advisory Panel Votes to Ease Restrictions on Controversial Peptide Compounds A Food and Drug Administration advisory panel has voted to loosen restrictions on a category of peptide compounds that have been at the center of an ongoing regulatory debate, according to a report from the BBC.
An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition
FDA Advisory Panel Breaks With Agency Staff, Backs Continued Access to Peptide Compounds A Food and Drug Administration advisory committee has voted in favor of preserving broader access to certain peptide-based compounds, setting up a notable clash with the agency's own staff recommendations, acco...
FDA Panel to Revisit Biden Peptide Ban as It Weighs Looser Rules
FDA Panel to Revisit Biden-Era Peptide Restrictions Amid Push for Regulatory Flexibility A Food and Drug Administration advisory panel is preparing to reexamine restrictions placed on a category of therapeutic peptides during the Biden administration, according to a report from Bloomberg Law News.
Compounded GLP-1s: Why doctors worry and the FDA is cracking down
Compounded GLP-1s: Why Doctors Worry and the FDA Is Cracking Down The explosive popularity of GLP-1 receptor agonists like semaglutide and tirzepatide for weight loss and diabetes management has spawned a booming secondary market: compounded versions of these drugs, sold at a fraction of brand-name...
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides As federal oversight of compounded GLP-1 medications and research peptides continues to evolve at the U.S.
Why Did Peptide Sciences Shut Down? Timeline, FDA Pressure, and What It Means for the Industry
Peptide Sciences, the largest gray-market research peptide vendor in the U.S., voluntarily shut down on March 6, 2026. A breakdown of the FDA enforcement actions, pharmaceutical lawsuits, and new legislation that led to the closure.
FDA Peptide Category 1 vs Category 2: Complete List and What It Means for Access
Understanding the FDA's Category 1 and Category 2 bulk drug substance classifications for peptides, which compounds fall into each group, and how 2026 reclassification proposals could reshape compounding pharmacy access.
Are Peptides Legal for Veterinary Use? FDA, DEA, and State Regulations
A detailed look at the legal framework governing peptide use in animals, including FDA animal drug rules, extra-label use under AMDUCA, DEA scheduling considerations, and state veterinary board regulations.
Peptide Patent Wars: Novo Nordisk, Eli Lilly, and the Fight Over GLP-1 Compounding
An analysis of the ongoing legal battles between pharmaceutical giants Novo Nordisk and Eli Lilly and the compounding pharmacy industry over GLP-1 receptor agonist patents, FDA shortage declarations, and patient access.
FDA Peptide Naming and Labeling Requirements: How Mislabeling Leads to Enforcement
FDA peptide labeling requirements are strict and frequently enforced. Learn how mislabeled peptide products trigger warning letters, seizures, and injunctions.
FDA's Evolving Stance on GHK-Cu and Cosmetic Peptide Ingredients
The FDA's regulatory approach to cosmetic peptides like GHK-Cu demonstrates the blurry line between cosmetics and drugs, with enforcement implications for the growing peptide skincare industry.
Are Peptide Supplements FDA Approved? What Consumers Need to Know
Most peptide supplements on the market are not FDA approved, and many are illegally marketed. Learn which peptides have FDA approval, how to identify legal products, and what "FDA approved" really means.
FDA Peptide Regulations 2026: What You Need to Know
Comprehensive overview of FDA peptide regulations in 2026, including bulk drug substance categories, compounding restrictions, and how recent actions affect peptide access.
Telehealth Peptide Prescribing Laws: State and Federal Guide
Navigate the legal framework for telehealth peptide prescribing, including federal regulations, state-by-state requirements, and provider and patient considerations.
Compounding Pharmacy Regulations: 503A vs 503B Explained
Understand the critical differences between 503A and 503B compounding pharmacies, how they affect peptide access, quality assurance, and regulatory compliance.
FDA Ruling: Peptides BPC-157 & TB-500 Impacted
FDA Category 2 Peptides: An Analysis of the 2023 Ruling and Its Impact on BPC-157, TB-500, and the Peptide Industry In 2023, the Food and Drug Administration (FDA) implemented a ruling with significant ramifications for the peptide industry, particularly impacting the availability and sourcing o...
DEA Scheduling of Peptides: Which Peptides Are Controlled Substances?
FDA Regulation and Peptide Scheduling: A Deep Dive into DEA Control Overview of the Regulatory Action The Drug Enforcement Administration (DEA) plays a crucial role in regulating peptides in the United States, primarily through its scheduling authority under the Controlled Substances Act (CSA).
Semaglutide: Prescription Laws by Country
Semaglutide Legal Status: A Global Analysis of Prescription Requirements and Regulatory Implications Overview of the Regulatory Action Semaglutide, marketed under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight management), has experienced a surge in global demand.
Mounjaro Legal? 2024 Prescription Guide
Here is the requested analysis: Tirzepatide (Mounjaro) Legal Status and Prescription Requirements in 2024: A Regulatory Analysis Tirzepatide, marketed as Mounjaro, has rapidly gained prominence in both diabetes management and, increasingly, weight loss.
FDA Warning Letters to Peptide Suppliers: 2024-2025 Trends
In recent years, the peptide industry has witnessed significant growth, fueled by the potential therapeutic benefits of peptides in treating a wide array of conditions.
FDA Crackdown on Compounded Semaglutide: What You Need to Know
The increasing popularity of semaglutide, a medication initially developed to treat type 2 diabetes and later approved for weight management, has led to a surge in its use and a corresponding rise in the compounding of this peptide by pharmacies.
How FDA Defines "Drug" vs "Research Chemical" for Peptides
In an era where scientific advancements have propelled peptides to the forefront of medical research, the distinction between a "drug" and a "research chemical" becomes crucial for researchers, pharmaceutical companies, and regulatory bodies.
GLP-1 Drug Shortage and FDA Compounding Guidelines Explained
In recent years, the pharmaceutical landscape has been significantly impacted by the emergence of GLP-1 receptor agonists, a class of drugs primarily used to treat type 2 diabetes and obesity.
FDA Enforcement Actions Against Peptide Sellers: Case Studies
In recent years, the peptide industry has witnessed significant growth, driven by advancements in biotechnology and increased interest in personalized medicine.